Repligen (NASDAQ:RGEN) Price Target Raised to $205.00

Repligen (NASDAQ:RGEN) had its target price upped by Royal Bank of Canada from $203.00 to $205.00 in a research report report published on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and issued a $180.00 price objective on shares of Repligen in a research note on Friday. Wolfe Research initiated coverage on Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. Finally, TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price target for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $183.36.

Repligen Stock Down 2.3 %

RGEN stock opened at $158.99 on Friday. The stock has a market cap of $8.91 billion, a P/E ratio of -429.69, a PEG ratio of 4.23 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $113.50 and a twelve month high of $203.13. The company’s 50 day moving average is $155.22 and its two-hundred day moving average is $148.79.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Research analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of RGEN. GTS Securities LLC acquired a new position in shares of Repligen during the fourth quarter worth about $264,000. Gordian Capital Singapore Pte Ltd purchased a new stake in Repligen in the 4th quarter valued at approximately $259,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Repligen by 12.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 235,343 shares of the biotechnology company’s stock valued at $33,875,000 after purchasing an additional 26,733 shares in the last quarter. Two Sigma Advisers LP increased its position in Repligen by 6.7% during the 4th quarter. Two Sigma Advisers LP now owns 134,800 shares of the biotechnology company’s stock worth $19,403,000 after purchasing an additional 8,500 shares during the period. Finally, Raiffeisen Bank International AG purchased a new position in shares of Repligen during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.